Summary

JB Chemicals & Pharmaceuticals Ltd announced a mixed performance for Q4 FY26, with revenue declining by 5% year-on-year to ₹904 crores and net profit after tax decreasing by 30% to ₹101 crores. However, for the full financial year 2026, the company reported a 6% revenue growth to ₹4,148 crores and an 8% increase in net profit after tax to ₹709 crores. The EBITDA margin for FY26 improved to 29%, driven by cost synergies and an improving business mix. While Q4 performance was impacted by operational realignments and one-off items, management expressed confidence in a progressive business improvement starting from Q1 FY27, with core business performance remaining robust.

Key Highlights

1. 1

   JB Chemicals & Pharmaceuticals Ltd reported Q4 FY26 revenue at ₹904 crores, experiencing a 5% de-growth year-on-year.

2. 2

   For the full financial year 2026, the company's revenue increased by 6% to ₹4,148 crores.

3. 3

   Net Profit after tax for Q4 FY26 declined by 30% to ₹101 crores, reflecting muted operational performance due to integration activities.

4. 4

   Full-year FY26 net profit after tax grew by 8% to ₹709 crores.

5. 5

   EBITDA margin for FY26 improved to 29% from 28% in FY25, indicating enhanced operational efficiency.

6. 6

   The India business demonstrated robust performance for FY26, growing 9% year-on-year to ₹2,461 crores.

7. 7

   Management expressed confidence in a progressive business improvement in the coming quarters, starting from April, with core business performance remaining robust despite Q4's operational realignment.